Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues

Oncology Reports

Volumn 10, Issue 1, 2003, Pages 223-228

  Merseburger, Axel S ^b,c,d   Kuczyk, Markus A ^d   Serth, Jürgen ^d   Bokemeyer, Carsten ^e   Young, Denise Y ^b   Sun, Leon ^c   Connelly, Roger R ^c   McLeod, David G ^a,c   Mostofi, Fathollah K ^b   Srivastava, Shiv K ^c   Stenzl, A ^e   Moul, Judd W ^a,c   Sesterhenn, Isabell A ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

bcl 2; Cancer; p53; Prostate; Radical prostatectomy; Recurrence; Tissue microarray

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER; TUMOR PROTEIN;

AGED; ARTICLE; BLOOD; ENZYME IMMUNOASSAY; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038340752     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.1.223     Document Type: Article

References (31)

1. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998. (Pubitemid 28331029)
2. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP and Sauter G: Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5: 1966-1975, 1999. (Pubitemid 29399245)
3. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G and Kallioniemi OP: Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59: 803-806, 1999. (Pubitemid 29086730)
4. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G and Kallioniemi OP: Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91: 1758-1764, 1999. (Pubitemid 29518772)
5. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S and Moul JW: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 156: 1511-1516, 1996. (Pubitemid 26307649)
6. Matsushima H, Kitamura T, Goto T, Hosaka Y, Homma Y and Kawabe K: Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol 158: 2278-2283, 1997. (Pubitemid 27481390)
7. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ and Roy-Burman P: Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 147: 92-101, 1995.
8. Kuczyk MA, Serth J, Bokemeyer C, Machtens S, Minssen A, Bathke W, Hartmann J and Jonas U: The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer 34: 679-686, 1998.
9. Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava SK and Moul JW: p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy (see comments). J Urol 162: 2040-2045, 1999.
10. Smith CV, Bauer JJ, Connelly RR, Seay T, Kane C, Foley J, Thrasher JB, Kusuda L and Moul JW: Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol 164: 1964-1967, 2000.
11. Ohori M, Wheeler TM and Scardino PT: The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 74: 104-114, 1994. (Pubitemid 24187618)
12. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 50: 125-128, 1966.
13. Mostofi FK, Sesterhenn IA and Sobin LH: Histological typing of new prostate tumors. International Histologic Classification of Tumors. No. 22. Waverly, New York, 1980.
14. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
15. Baker SJ, Markowitz S, Fearon ER, Willson JK and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915, 1990.
16. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993. (Pubitemid 23132161)
17. Voeller HJ, Sugars LY, Pretlow T and Gelmann EP: p53 oncogene mutations in human prostate cancer specimens. J Urol 151: 492-495, 1994 (Pubitemid 24047041)
18. Van Veldhuizen PJ, Sadasivan R, Garcia F, Austenfeld MS and Stephens RL: Mutant p53 expression in prostate carcinoma. Prostate 22: 23-30, 1993. (Pubitemid 23075490)
19. Quinn DI, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, Turner JJ, Delprado W, Finlayson JF, Stricker PD, Grygiel JJ and Sutherland RL: Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 60: 1585-1594, 2000. (Pubitemid 30183429)
20. Byar DP and Mostofi FK: Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer 30: 5-13, 1972.
21. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O and Korsmeyer SJ: bcl-2 Inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67: 879-888, 1991. (Pubitemid 121001502)
22. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL and Korsmeyer SJ: Cloning the chromosomal breakpoint of t(14; 18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41: 899-906, 1985. (Pubitemid 15243395)
23. Keshgegian AA, Johnston E and Cnaan A: Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 110: 443-449, 1998. (Pubitemid 28443436)
24. Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE and Hamdy FC: Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate 37: 223-229, 1998. (Pubitemid 28524654)
25. Bylund A, Stattin P, Widmark A and Bergh A: Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy. Radiother Oncol 49: 143-148, 1998. (Pubitemid 29017908)
26. Moul JW, Connelly RR, Mooneyhan RM, Zhang W, Sesterhenn IA, Mostofi FK and McLeod DG: Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol 162: 394-397, 1999. (Pubitemid 29434347)
27. Miller GJ and Cygan JM: Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 152: 1709-1713, 1994. (Pubitemid 24322612)
28. Mucci NR, Akdas G, Manely S and Rubin MA: Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 31: 406-414, 2000. (Pubitemid 30262860)
29. Moch H, Kononen T, Kallioniemi OP and Sauter G: Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 8: 14-20, 2001.
30. Srivastava M, Bubendorf L, Srikantan V, Fossom L, Nolan L, Glasman M, Leighton X, Fehrle W, Pittaluga S, Raffeld M, Koivisto P, Willi N, Gasser TC, Kononen J, Sauter G, Kallioniemi OP, Srivastava S and Pollard HB: ANX7, a candidate tumor suppressor gene for prostate cancer. Proc Natl Acad Sci USA 98: 4575-4580, 2001. (Pubitemid 32295018)
31. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP and Gelmann EP: Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 60: 6111-6115, 2000.